Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{3-[(7ar,12as,12bs)-7-Oxo-1,3,4,6,7,7a,12a,12b-Octahydroindolo[2,3-a]quinolizin-12(2h)-yl]propyl}propane-2-sulfonamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
N-{3-[(7ar,12as,12bs)-7-Oxo-1,3,4,,6,,7,,7a,,12a,, and Octahydroindolo[2. This compound is a synthetic small molecule belonging to the beta-carboline class of organic compounds. It has a molecular formula of C21H29N3O3S and a molecular weight of approximately 403.54 g/mol[2][5][8]. The structure features an indoloquinolizine core with a sulfonamide side chain. There are no approved medical indications or clinical trials for this compound as of now; it is considered experimental and not approved by any major regulatory agency for therapeutic use[2][4]. Its mechanism of action and biological targets have not been characterized in the literature or public databases.
- Other names
- N-{3-[(12bS)-7-Oxo-1H,2H,3H,4H,6H,7H,12H,12bH-indolo[2,3-a]quinolizin-12-yl]propyl}propane-2-sulfonamideN-{3-[ ( 7ar , 12as , 12bs ) - 7 - Oxo - 1 , 3 , 4 , 6 , 7 , 7a , 12a , 12b - Octahydroindolo [2 ,3-a ] Quinolizin - ... (various stereochemical variants)
Beyond the preview
Go deeper on N-{3-[(7ar,12as,12bs)-7-Oxo-1,3,4,6,7,7a,12a,12b-Octahydroindolo[2,3-a]quinolizin-12(2h)-yl]propyl}propane-2-sulfonamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-{3-[(7ar,12as,12bs)-7-Oxo-1,3,4,6,7,7a,12a,12b-Octahydroindolo[2,3-a]quinolizin-12(2h)-yl]propyl}propane-2-sulfonamide.